LONG-TERM EFFECTS OF A CONVERTING-ENZYME-INHIBITOR AND A CALCIUM-CHANNEL BLOCKER ON URINARY ALBUMIN EXCRETION IN PATIENTS WITH ESSENTIAL-HYPERTENSION

被引：40

作者：

BIGAZZI, R

BIANCHI, S

BALDARI, D

SGHERRI, G

BALDARI, G

CAMPESE, VM

机构：

[1] UO di Nefrologia e Dialisi, Spedali Riuniti, Livorno

[2] Division of Nephrology, University of Southern California, Los Angeles, CA

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1993年 / 6卷 / 02期

关键词：

ESSENTIAL HYPERTENSION; MICROALBUMINURIA; ANGIOTENSIN CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; ENALAPRIL; NICARDIPINE;

D O I：

10.1093/ajh/6.2.108

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Microalbuminuria in patients with essential hypertension is associated with increased incidence of cardiovascular morbidity and mortality. Reduction of urinary albumin excretion (UAE) with therapy could reduce cardiovascular events. The long-term effect of commonly used antihypertensive agents on UAE has not been properly investigated. In the present study, we have prospectively studied the effects of therapy for 24 months with a converting enzyme inhibitor, enalapril, or a calcium channel blocker, nicardipine, on UAE in 40 patients with essential hypertension and microalbuminuria. Enalapril and nicardipine were equally effective in reducing arterial pressure. However, enalapril decreased UAE from 77.1 +/- 10.4 to 30.4 +/- 7.9 mg/24 h after 1 year, and to 24.7 +/- 4.8 (P < .01) after 2 years of therapy. UAE however, did not change in patients treated with nicardipine (from 65.2 +/- 12 to 73 +/- 14 after 1 year, and to 52.7 +/- 21 mg/24 h after 2 years of therapy). The impact of reducing UAE on overall cardiovascular morbidity and mortality and on future progression of renal failure in patients with essential hypertension remains to be established.

引用

页码：108 / 113

页数：6

共 45 条

[41] Anderson S., Rennke H.G., Brenner B.M., Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat, J Clin Invest, 77, pp. 1993-2000, (1986)
[42] Zatz R., Dunn R., Meyer T.W., Et al., Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension, J Clin Invest, 77, pp. 1925-1930, (1986)
[43] Raij L., Shultz P.J., Tolins J.P., Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors, J Hypertens, 7, pp. S33-S37, (1989)
[44] Morelli E., Loon N., Meyer T., Et al., Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy, Diabetes, 39, pp. 2-8, (1990)
[45] Remuzzi A., Schieppati A., Battaglia C., Et al., Angiotensinconverting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatrémie hypertensive syndrome, Am J Kidney Dis, 14, pp. 170-177, (1989)

← 1 2 3 4 5 →